engleski

Visfatin is not associated with inflammatory markers in patients on hemodialysis

Patients with chronic renal disease often suffer from diverse cardiovascular complications. Endothelial dysfunction has been involved in development of different forms of the cardiovascular diseases, including chronic renal disease. In recent years, ubiquitous adipokine called visfatin has been considered as a novel marker of endothelial dysfunction and inflammation. Thus, the aim of our study was to investigate the association of serum visfatin concentrations and well-established markers of cardiovascular risk in the patients on hemodialysis. Serum and plasma samples from 66 patients (40 males and 26 females) treated by hemodialysis were analysed for visfatin, fibrinogen, CRP and PAI-1 levels. Visfatin was determined by ELISA method while CRP, fibrinogen and PAI-1 were obtained by standard laboratory methods. Visfatin did not correlate with the studied markers of inflammation (CRP (r =-0.05, P = 0.152) ; PAI-1 (r = -0.08, P = 0.558) and fibrinogen (r = 0.04, P = 0.772)). Statistically significant correlation between visfatin level and fibrinogen (r = 0.51 ; P = 0.008) and the time on dialysis (r = 0.70 ; P < 0.001) was observed in female patients. In conclusion, visfatin is not associated with CRP, fibrinogen and PAI-1 in patients on hemodialysis.

chronic renal disease; inflamation; visfatin

nije evidentirano